New York TimesLean L·
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
Read at New York Times →
Politics · 1 sources covering this
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
Coverage spectrum
1 L · 0 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/04d9d599558e4215f8c09d03c1296936a365478a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working"></iframe>
